|
28 December 2005
AstraZeneca Signs Collaboration Agreement with Targacept for New Neuronal Nicotinic Receptor Compounds
|
| Phase II compound for improving cognitive deficits in Alzheimer’s Disease and Schizophrenia included in agreement.
AstraZeneca today announced that it has signed an exclusive global licensing and research collaboration agreement with Targacept Inc. for the development and commercialization of Targacept's phase II compound, TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders. The four-year research collaboration also allows for the development of other compounds that act on neuronal nicotinic receptors (NNRs).
|
 |
23 December 2005
Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca’s Ability To Generate Novel Cancer Treatments
|
AstraZeneca today announced an agreement to acquire KuDOS Pharmaceuticals Limited, a privately-owned UK biotechnology company, focused on the discovery and development of oncology therapies based on the inhibition of DNA repair. The total share capital of the company will be purchased for $210m cash, subject to debt and working capital adjustment. The transaction is expected to close early in 2006.
|
|
22 December 2005
AstraZeneca and AtheroGenics Announce Late Stage Licensing and Commercialisation Agreement for Novel Atherosclerosis Drug AGI-1067
|
AstraZeneca today announced that it has entered into a licensing deal with AtheroGenics, Inc. (Nasdaq: AGIX) for the global development and commercialisation of their anti-inflammatory cardiovascular product candidate, AGI-1067. AGI-1067 is an investigational oral drug for the treatment of atherosclerosis, the underlying disease process that leads to heart attacks and strokes and is currently in Phase III development in the ARISE (Aggressive Reduction of Inflammation Stops Events) trial.
|
|
14 December 2005
EU Committee for Orphan Medicinal Products Recommends Orphan Drug Designation for ZD6474 (ZACTIMA™) for the Investigation of a Rare form of Thyroid Cancer |
AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA™) for the treatment of patients with medullary thyroid cancer in the European Union (EU). Final adoption of the opinion is expected from the European Commission in early 2006.
|
|
9 December 2005
Data Show Survival Benefit For Arimidex™ In Early Breast Cancer
|
Data presented today at the San Antonio Breast Cancer Symposium (SABCS), Texas has found that 'Arimidex' (anastrozole) is the first aromatase inhibitor (AI) to provide an overall survival benefit, compared with tamoxifen, in the treatment of hormone-sensitive early breast cancer.
|
|
8 December 2005
AstraZeneca and Protherics Announce Late Stage Licensing Agreement On CytoFab™ |
AstraZeneca today announced a global development and commercialisation agreement for Protherics anti-sepsis product CytoFab™. CytoFab™ is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).
|
|
22 November 2005
AstraZeneca Commences Patent Infringement Litigation Against Ranbaxy Laboratories |
AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Ranbaxy Laboratories for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium).
|
|
9 November 2005
AstraZeneca Commences Patent Infringement Litigation Against Teva |
AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. for willful infringement of AstraZeneca’s substance patent protecting Seroquel.
|
|
31 October 2005
FDA Grants ZD6474 (Zactima™) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer
|
AstraZeneca announced today that the US Food and Drug Administration (FDA) has granted ZD6474 (ZACTIMA™) Orphan Drug designation for the treatment of patients with follicular, medullary, anaplastic, and locally advanced and metastatic papillary thyroid cancer. ZD6474 is a unique once-daily oral therapy that selectively targets key cell signalling pathways involved in tumour growth and spread including VEGF (Vascular endothelial growth factor) receptor signalling and EGF (Epidermal growth factor) receptor signalling. ZD6474 also inhibits RET kinase, which drives the growth and survival of certain tumours, and is believed to be an important pathway in medullary thyroid cancer.
|
|
27 October 2005
THIRD QUARTER AND NINE MONTHS RESULTS 2005 |
"A strong third quarter with sales up 9 percent and Earnings per Share up 52 percent: year end targets increased."
AstraZeneca PLC Third Quarter and Nine Months Results 2005
|
|
21 October 2005
BOLDER II STUDY CONFIRMS THERAPEUTIC POTENTIAL OF SEROQUEL IN BIPOLAR DEPRESSION
|
|
|
18 October 2005
NEXIUM ANDA |
AstraZeneca has received a notice from Ranbaxy Pharmaceuticals Inc. that Ranbaxy Laboratories Limited has submitted an Abbreviated New Drug Application (ANDA) for esomeprazole magnesium delayed-release capsules, 20mg and 40mg, containing Paragraph IV Certifications of invalidity and/or non-infringement with respect to certain AstraZeneca US patents listed in the Orange Book in reference to Nexium, the latter of which expires in 2018.
|
|
28 September 2005
SEROQUEL ANDA
|
|
|
23 September 2005
ASTRAZENECA SUBMITS NEW DRUG APPLICATION (NDA) TO FDA FOR SYMBICORT® MAINTENANCE TREATMENT OF ASTHMA
|
AstraZeneca has announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of SYMBICORT® (budesonide/formoterol) for the maintenance treatment of asthma.
|
|
19 September 2005
NIMH-FUNDED STUDY EXAMINES THE USE OF ANTIPSYCHOTIC MEDICATIONS FOR THE TREATMENT OF SCHIZOPHRENIA
|
|
|
15 September 2005
ASTRAZENECA APPOINTS TONY ZOOK AS EXECUTIVE VICE PRESIDENT for NORTH AMERICA |
AstraZeneca today announced the appointment of Tony Zook as Executive Vice President for North America, and President and Chief Executive Officer of AstraZeneca US, effective from January 1, 2006.
|
|
28 July 2005
SECOND QUARTER RESULTS 2005 |
"Record sales and operating profit in the first half year: year end targets increased."
|
|
28 July 2005
ASTRAZENECA PLC
|
The Board of AstraZeneca PLC announces the appointment of David R Brennan as Chief Executive with effect from 1 January 2006 upon the retirement at that time of Sir Tom McKillop.
|
|
27 July 2005
ASTRAZENECA AND SCHERING AG ANNOUNCE COLLABORATION AND LICENSING AGREEMENT IN THE AREA OF ANTI-INFLAMMATORY AGENTS |
AstraZeneca and Schering AG, Germany, today announced that they have entered into a research collaboration and licensing agreement in the area of Selective Glucocorticoid Receptor Agonists (SEGRAs) which represent a new class of anti-inflammatory agents.
|
|
27 July 2005
ASTRAZENECA AND ASTEX ANNOUNCE NEW ANTI-CANCER DRUG DISCOVERY ALLIANCE
|
AstraZeneca and Astex form new strategic alliance to discover, develop and commercialise novel small molecule inhibitors of the anti-cancer target Protein Kinase B (Akt)
AstraZeneca and Astex Therapeutics Limited today announced a new alliance to discover, develop and commercialise novel small molecule inhibitors of Protein Kinase B (PKB; also known as Akt) for use as anti-cancer agents.
|
|
11 July 2005
ASTRAZENECA AND AVANIR ANNOUNCE GLOBAL ALLIANCE TO DISCOVER AND DEVELOP NOVEL REVERSE CHOLESTEROL TRANSPORT ENHANCING COMPOUNDS |
AstraZeneca today announced an exclusive global licensing and research collaboration agreement with Avanir to discover, develop and commercialise Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease.
|
|
4 July 2005
ASTRAZENECA TO START PHASE III TRIALS WITH ZACTIMA TM (ZD6474) – A NOVEL TARGETED LUNG CANCER TREATMENT
|
AstraZeneca announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 – now to be known by its trade name, ZACTIMATM. Recruitment to Phase III studies evaluating the anti-tumour activity of ZACTIMATM in non-small cell lung cancer (NSCLC) will begin in the next few months.
|
|
1 July 2005
ASTRA TECH EXPANDS THROUGH DENTAL BUSINESS ACQUISITION
|
Medical device company Astra Tech AB, a subsidiary of AstraZeneca PLC, is acquiring Cresco Ti Systems from its primary owners SEB Företagsinvest, Credit Suisse Innoventure Capital AG, and Banque Cantonale Vaudoise. The deal represents less than one per cent of AstraZeneca’s net assets.
|
|
28 June 2005
ASTRAZENECA'S BREAST CANCER TREATMENT ARIMIDEX® GRANTED NEW INDICATION ENABLING WIDER ACCESS FOR POSTMENOPAUSAL WOMEN |
AstraZeneca today announced that 'Arimidex' (anastrozole) has been granted a new indication from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, which has acted as the Reference Member State for the European Mutual Recognition Variation Procedure leading to further approvals in five other European countries - Austria, Germany, Italy, Portugal and Spain.
|
|
15 June 2005
ASTRAZENECA REFUTES EC’S FINDINGS IN LOSEC DOMINANCE CASE AND APPEALS DECISION
|
AstraZeneca announced today that it does not accept the European Commission’s decision that it infringed Article 82 EC during the marketing of Losec (omeprazole) in the 1990s, and will appeal the decision to fine the company 60 million Euros to the Courts.
|
|
23 May 2005
SYMBICORT® SINGLE INHALER THERAPY™ GIVES GREATER IMPROVEMENT IN ASTHMA CONTROL AND REQUIRES LESS INHALERS COMPARED TO SERETIDE™ |
AstraZeneca today announced that its novel treatment regimen, SYMBICORT® Single Inhaler TherapyTM delivers greater improvement in key measures of asthma control and simplifies management of the disease when compared to SeretideTM (fluticasone/salmeterol).
|
|
11 May 2005
EPO RULES SYMBICORT® COPD PATENT VALID
|
AstraZeneca today announced that the European Patent Office (EPO) has ruled that the European patent for Symbicort® in the treatment of Chronic Obstructive Pulmonary Disease (COPD) is still valid, despite a challenge by generic manufacturers.
|
|
4 May 2005
FIRST RESULTS FROM SAINT I TRIAL SHOW ASTRAZENECA’S CEROVIVE (NXY-059) DEMONSTRATES A REDUCTION IN DISABILITY IN PATIENTS WITH ACUTE ISCHEMIC STROKE
|
SAINT II and CHANT trials for CEROVIVE will continue as planned
AstraZeneca today announced that a first analysis of data from the SAINT I trial involving more than 1700 patients shows a statistically significant reduction versus placebo on the primary outcome of disability after an acute ischemic stroke (p= 0.038), as measured by the Modified Rankin Scale (MRS). However, on the National Institute of Health Stroke Scale (NIHSS), there was no significant difference between the treatment groups in measurement of change in neurological impairment. The clinical significance of these findings need to be assessed in light of the outcome of SAINT II and CHANT.
|
|
28 April 2005
FIRST QUARTER RESULTS 2005
|
“Record quarterly profits, with first quarter Earnings per Share up 33 percent. Sales up 9 percent.”
|
|
21 April 2005
ASTRAZENECA FULFILLS APPROVAL COMMITMENT TO MAKE 5MG DOSE OF CRESTOR AVAILABLE IN EU |
AstraZeneca announced today that agreement has been reached under the EU arbitration procedure on label wording for a 5mg dose of CRESTOR, the cholesterol lowering treatment, paving the way for its availability across the European Union
|
|
1 April 2005
FDA APPROVES INTRAVENOUS FORMULATION FOR NEXIUM®
|
AstraZeneca today announced that a new administration formulation for its prescription proton pump inhibitor NEXIUM ® (esomeprazole magnesium) has been approved by the US Food and Drug Administration (FDA). NEXIUM I.V. is now approved as an intravenous infusion or injection for the short-term treatment (up to 10 days) of gastroesophageal reflux disease (GERD) patients, with a history of erosive esophagitis, who are unable to take capsules.
|
|
15 March 2005
FDA REJECTS PUBLIC CITIZEN’S PETITION FOR ASTRAZENECA’S CRESTOR®
|
|
|
14 March 2005
ASTRAZENECA PLC BOARD ANNOUNCEMENT |
AstraZeneca PLC today announced the appointment to the Board of David R. Brennan as an Executive Director with effect from 14 March 2005.
|
|
9 March 2005
EPO RULES SYMBICORT® COMBINATION PATENT STILL VALID |
AstraZeneca today announced that the European Patent Office (EPO) has ruled that the European combination patent for Symbicort® is still valid, despite a challenge by several generic manufacturers.
|
|
4 March 2005
STUDY FINDS SEROQUEL EFFECTIVE AND WELL TOLERATED |
AstraZeneca today announced results from a study involving elderly patients with Alzheimer’s disease (AD) treated with the atypical antipsychotic SEROQUEL (quetiapine) at the annual meeting of the American Association of Geriatric Psychiatry in San Diego, USA. The study found that SEROQUEL at 200 mg/day was effective in reducing agitation in elderly patients with AD without leading to a decline in cognitive function. SEROQUEL was also generally well tolerated with no incidence of cerebrovascular adverse events during treatment, which have been associated with the use of other atypical antipsychotics in this patient population. In the 30-day follow up, one cerebrovascular event was reported in the 100mg/day group.
|
|
23 February 2005
FDA APPROVES ASTRAZENECA’S ATACAND® (CANDESARTAN CILEXETIL) FOR THE TREATMENT OF HEART FAILURE |
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved its angiotensin receptor blocker (ARB) ATACAND® (candesartan cilexetil) for the treatment of heart failure (New York Heart Association Class II-IV and ejection fraction less than or equal to 40 percent) to reduce the risk of death from cardiovascular causes and reduce hospitalisations from heart failure. ATACAND is the first ARB in the US to receive an indication for reducing both cardiovascular mortality and hospitalisations for heart failure.
|
|
27 January 2005
FOURTH QUARTER AND FULL YEAR RESULTS 2004 |
“Strong earnings performance for 2004; good earnings growth anticipated despite recent disappointments.”
|
|
19 January 2005
FURTHER CLINICAL INFORMATION REQUESTED ON EXANTA® (XIMELAGATRAN) FOR THE PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION IN EUROPE |
Following the review by the French Regulatory Authority (AFSSAPS) of the Exanta® regulatory submission made in December 2003 AstraZeneca today announced receipt of a request for more information before the drug can be considered for approval of long-term use in Europe.
|
|
4 January 2005
GEFITINIB (IRESSA™) MARKETING AUTHORISATION APPLICATION WITHDRAWN IN EU |
AstraZeneca today announced that it is withdrawing the European Marketing Authorisation Application (MAA) for IRESSA™ (gefitinib) in treating patients with non-small cell lung cancer (NSCLC) from the European Medicines Agency (EMEA).
|
|